Gilead Sciences, Inc. $GILD Shares Acquired by Triasima Portfolio Management inc.

Triasima Portfolio Management inc. lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,111 shares of the biopharmaceutical company’s stock after purchasing an additional 4,445 shares during the period. Triasima Portfolio Management inc.’s holdings in Gilead Sciences were worth $4,341,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Sage Mountain Advisors LLC lifted its holdings in Gilead Sciences by 10.9% during the 3rd quarter. Sage Mountain Advisors LLC now owns 8,604 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 847 shares during the last quarter. Inscription Capital LLC raised its position in shares of Gilead Sciences by 35.7% during the 3rd quarter. Inscription Capital LLC now owns 4,656 shares of the biopharmaceutical company’s stock worth $517,000 after acquiring an additional 1,224 shares in the last quarter. Americana Partners LLC purchased a new stake in Gilead Sciences during the third quarter worth approximately $384,000. Root Financial Partners LLC boosted its holdings in Gilead Sciences by 11.1% in the third quarter. Root Financial Partners LLC now owns 2,079 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 208 shares in the last quarter. Finally, Turtle Creek Wealth Advisors LLC increased its stake in Gilead Sciences by 60.7% in the third quarter. Turtle Creek Wealth Advisors LLC now owns 7,215 shares of the biopharmaceutical company’s stock valued at $801,000 after purchasing an additional 2,726 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent analyst reports. TD Cowen boosted their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. BMO Capital Markets reissued an “outperform” rating on shares of Gilead Sciences in a research report on Tuesday, January 13th. Argus upped their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Needham & Company LLC lifted their target price on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, HSBC upped their target price on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research report on Wednesday, December 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $133.28.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the transaction, the insider owned 107,193 shares in the company, valued at approximately $13,491,310.98. The trade was a 20.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Deborah H. Telman sold 53,646 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the sale, the executive vice president directly owned 43,676 shares of the company’s stock, valued at $5,365,596.60. This represents a 55.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 136,757 shares of company stock valued at $16,951,612. Insiders own 0.27% of the company’s stock.

Gilead Sciences Trading Down 1.0%

Shares of GILD stock opened at $123.61 on Tuesday. The company has a market capitalization of $153.36 billion, a P/E ratio of 19.21, a price-to-earnings-growth ratio of 0.66 and a beta of 0.33. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The business’s 50 day moving average is $123.49 and its two-hundred day moving average is $118.20. Gilead Sciences, Inc. has a twelve month low of $91.84 and a twelve month high of $128.70.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period last year, the company earned $2.02 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.